News


All series


All News

The FDA granted approval to countless treatments across cancer types throughout 2019 until the end of the year, with a final approval on December 31<sup>st&nbsp;</sup>for the first BRCA targeted therapy in pancreatic cancer. Following the excitement for a new year of further advances,&nbsp;Targeted Oncology&nbsp;followers on Twitter shared their thoughts on some of the most impactful FDA approvals in 2019.

The FDA released a draft guidance document entitled &ldquo;Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Guidance for Industry&rdquo; to clarify the evidence required to prove the effectiveness of drugs and biologics. The statement is a supplement for the 1998 guidance entitled &ldquo;Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.&rdquo; The draft guidance is designed to aid the submission of&nbsp; new drug applications, biologics license applications, or applications for supplemental indications.

In an interview with&nbsp;Targeted Oncology, Nizar Bahlis, MD, discussed the updated findings from the MAIA trial, which he presented at the 2019 ASH Annual Meeting. He highlighted the updates to the PFS, OS, and overall response rate data, as well as some other areas daratumumab is under investigation now following the positive data from this trial.&nbsp;

Individuals with obesity who were diagnosed with locally advanced or metastatic clear cell renal cell carcinoma achieved longer overall survival than patients of normal weight in select groups of an independent cohort study, which evaluated overall survival and the transcriptomic differences in the primary tumor and peritumoral adipose tissue in adult patients with metastatic clear cell renal cell carcinoma.

In December 2019, the FDA approved a number of new treatments in lung cancer, pancreatic cancer, urothelial carcinoma, breast cancer, and prostate cancer. A&nbsp;tissue complete assay was also approved by the FDA for use in a clinical trial evaluating pembrolizumab.

Adult patients&nbsp;with&nbsp;deleterious or suspected deleterious&nbsp;germline&nbsp;<em>BRCA</em>-mutated metastatic pancreatic adenocarcinoma who have not had disease progression on at least 16 weeks of first-line platinum-based chemotherapy may now receive maintenance therapy with the&nbsp;PARP inhibitor olaparib, according to an approval from the FDA.

In an interview with&nbsp;Targeted Oncology&nbsp;at the 2019 Ruesch Center Symposium, Benjamin Weingberg, MD, shared key points from his discussion on mining the microbiome in patients with colorectal cancer and summarized the treatment landscape for patients with metastatic disease. He also discussed an upcoming basket trial that uses liquid biopsies to place patients on treatment plans that will be most effective for their individual needs.

The combination of off-the-shelf, antibody-targeted natural killer cells and IL-15 superagonist N-083 with low-dose metronomic chemoradiation, adenoviral and year tumor-associated antigen vaccines, and a PD-L1 checkpoint inhibitor had ongoing durable complete responses in patients with triple-negative breast cancer who failed standard-of-care treatment, according to a press release from NantKwest Inc., manufacturer of the NK cell-based therapy.

The Cchek Prostate Cancer Confirmation test&mdash;which utilizes artificial intelligence, flow cytometry, and liquid-biopsy technology to detect prostate cancer&mdash;has been commercially launched, according to Anixa Biosciences, Inc., developer of the test. Once it becomes available, this test will reduce the need for expensive and invasive biopsy procedures to diagnose patients with prostate cancer in certain patients.<br /> &nbsp;

Recent study results suggest that guideline recommendations for biomarker testing in metastatic colon cancer are not consistent with real-world care. A retrospective review of the COTA Real World Data database showed suboptimal adherence to testing guidelines for RAS, BRAF, and microsatellite instability (MSI)/mismatch repair deficiency in this patient population.

In an interview with Targeted Oncology, Ian W. Flinn, MD, PhD, discussed the results from the ZUMA-2 trial which evaluated the efficacy and safety of KTE-X19, a CAR T-cell therapy, in patients with relapsed/refractory mantle cell lymphoma. He highlighted how unique this product is compared to other CAR T-cell therapies and where he believes it will fit into the treatment landscape for patients with mantle cell lymphoma.

Tucatinib developer, Seattle Genetics, Inc., has submitted a new drug application to the FDA for tucatinib in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received at least 3 prior HER2-directed drugs alone or in combination with other drugs, in the neoadjuvant, adjuvant, or metastatic setting, according to a press release.<br /> &nbsp;

A new drug application for selinexor has been submitted to the FDA for the treatment of patients with relapsed or refractory diffuse large b-cell lymphoma who have had at least 2 prior multi-drug therapies,and who are ineligible for stem cell transplantation, including chimeric antigen receptor T-cell therapy, according to a press release from Karypharm Therapeutics, developer of selinexor.<br /> &nbsp;

The first half-yearly follow-up&nbsp;results from a phase I study of ilixadencel monotherapy in patients with advanced gastrointestinal stromal tumors will be presented by Alex Karlsson-Parra, MD, PhD on February 6, 2020, during poster session A, at the Clinical Immuno-Oncology Symposium, according to a press release from Immunicum AB, where Karlsson-Parra serves as the chief executive officer.<br /> &nbsp;